HELX
Franklin Genomic Advancements ETF
HELX is an actively managed portfolio of global equity securities of companies relevant to genomic discovery.
Global
EQUITY
Active
MANAGEMENT STYLE
$ 21.5 M
ASSETS UNDER MGMT
50 bp
EXPENSES
Fund Basics
| Inception date | Feb 25, 2020 |
| Regulation | Open-Ended Fund |
| Fund Website | link... |
| Distributions | Annually |
| Currency | USD |
| Holdings Transparency | Full |
| Derivatives-based | No |
| Options available | Yes |
| Currency hedged | No |
| Fund of funds | No |
Top 10 Holdings
| NATERA INC | 6.9 % |
| GUARDANT HEALTH, INC. | 6.8 % |
| KRYSTAL BIOTECH, INC. | 4.6 % |
| MEDPACE HOLDINGS, INC. | 4.4 % |
| INSMED INC | 4.4 % |
| BRIDGEBIO PHARMA, INC. | 3.9 % |
| ALNYLAM PHARMACEUTICALS INC | 3.6 % |
| UNITED THERAPEUTICS CORP | 3.5 % |
| ADAPTIVE BIOTECHNOLOGIES CORP. | 3.3 % |
| LIGAND PHARMACEUTICALS-CL B | 3.0 % |
Constituent Breakdown
| Number of holdings | 67 |
| Herfindahl-Hirschman Index | 300 |
| Wgt avg mkt cap (mns) | $57,914 |
| Large cap (>$10bn) | 63.4% |
| Mid cap ($2-10bn) | 25.6% |
| Small cap (<$2bn) | 2.9% |
| Developed mkts. | 94.5% |
| Emerging mkts. | 2.2% |
Sector Breakdown
Country Exposure
 |
UNITED STATES | 85.1 % |
 |
BRITAIN | 2.8 % |
 |
GERMANY | 2.8 % |
 |
NETHERLANDS | 2.3 % |
 |
SOUTH KOREA | 1.9 % |
 |
SWITZERLAND | 0.7 % |
 |
IRELAND | 0.6 % |
Historical Performance
Standardized Performance (as of 03/31/2026)
| YTD | 1 YR | 2 YR | 3 YR | 5 YR | 10 YR | 20 YR | Incep. | |
|---|---|---|---|---|---|---|---|---|
| Price Returns | -9.0% | 22.4% | 0.5% | 2.8% | -5.3% | -- | -- | 5.4% |
| Dividend Yield | 0.0% | 0.5% | 0.2% | 0.1% | 0.1% | -- | -- | 0.1% |
| Total Returns | -9.0% | 22.9% | 0.6% | 3.0% | -5.2% | -- | -- | 5.6% | Ann. Volatility | 24.2% | 24.2% | 22.0% | 20.4% | 24.3% | -- | -- | 27.5% |
Market Correlations
| versus... | Beta | R-squared |
| S&P 500 | 0.93 | 54% |
| MSCI EAFE | 0.94 | 48% |
| MSCI Emg Mkts | 0.74 | 38% |
Liquidity Measures
| Avg. volume (000) | 1 |
| ADV traded (mns) | $0 |
| Turnover | 0.2% |
| Avg. Bid/Ask (% of price) | 0.52% |
Technical Indicators
| 30d moving avg. (EMA) | $33.67 |
| Relative strength (RSI) | 48 |
| MACD/Signal | 0.22/0.20 |
| Bollinger Bands (Upper/Lower) | $35.41/$31.71 |
| Short interest (% of AUM) | 0.4% |
Distributions
Top Ten Comparable ETFs only shown here. For an extended list become an Individual or Professional subscriber. Start your FREE trial
Comparable ETFs Based on Overlap
| Ticker | Fund Name | Overlap vs. HELX |
Expenses vs. HELX |
ALTAR Score™ vs. HELX |
|---|---|---|---|---|
| PTH | Invesco Dorsey Wright Healthcare Momentum ETF | 30.0% | +10 bp | -0.2% |
| IBBQ | Invesco Nasdaq Biotechnology ETF | 27.9% | -31 bp | +1.3% |
| IBB | iShares Biotechnology ETF | 27.8% | -5 bp | +0.4% |
| HTEC | ROBO Global Healthcare Technology and Innovation ETF | 27.8% | +18 bp | +3.5% |
| BBH | VanEck Biotech ETF | 27.0% | -15 bp | +5.7% |
| WDNA | WisdomTree BioRevolution Fund | 26.7% | -5 bp | -2.0% |
| GNOM | Global X Genomics & Biotechnology ETF | 25.6% | 0 bp | -2.3% |
| FBT | First Trust NYSE Arca Biotechnology Index Fund | 24.9% | +6 bp | +3.1% |
| BMED | Future Health ETF | 23.2% | +35 bp | +2.0% |
| BBP | Virtus LifeSci Biotech Products ETF | 23.1% | +29 bp | -2.8% |
Risk and Returns: HELX vs. Comps (1 YR)
Notes: Top 10 overlapping ETFs. Funds with insufficient history not shown. Some funds may overlap. Hover over data point for ticker symbol.
Content on this tab for Individual & Professional subscribers only. Start your FREE trial
Results & Estimates (USD)
| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | ||
|---|---|---|---|---|---|---|---|---|---|
| Sales per share | -- | -- | -- | -- | -- | -- | -- | ||
| change (%) | -- | -- | -- | -- | -- | -- | -- | ||
| Earnings per share | -- | -- | -- | -- | -- | -- | -- | ||
| change (%) | -- | -- | -- | -- | -- | -- | -- | ||
| Dividends per share | -- | -- | -- | -- | -- | -- | -- | ||
| change (%) | -- | -- | -- | -- | -- | -- | -- | ||
| Book value per share | -- | -- | -- | -- | -- | -- | -- | ||
| change (%) | -- | -- | -- | -- | -- | -- | -- |
Return on Equity
Net Margins
Content on this tab for Individual & Professional subscribers only. Start your FREE trial
Valuation Metrics
| Fwd Est | 2025 | 2026 | 2027 | |
| Price-to-sales | --x | --x | --x | --x |
| Price-to-earnings | --x | --x | --x | --x |
| Price-to-cash flow | --x | --x | --x | --x |
| Price-to-growth | --x | --x | --x | --x |
| Price-to-book value | --x | --x | --x | --x |
| Yield | --% | --% | --x | --% |
Based on closing prices from 4/29/2026
Peer Group Comparison Sample data. Subscribe for access.
Price-to-Earnings
Price-to-Sales
Price-to-Book Value
Price-to-Cash Flow
Price-to-Growth
Dividend Yield
Historical Valuation Trends Sample data. Subscribe for access.
SHOWING:
Price-to-Earnings
Price-to-Earnings
Notes: Based on adjusted historical results for current fund constituents. May differ from results achieved by past fund constituents. Max P/E of 100x.
Some content on this tab for Individual & Professional subscribers only. Start your FREE trial
ETF Research Center Rating
-1.0%
ALTAR SCORE™
2nd
PERCENTILE
AVOID
ETFRC RATING
There are 586 funds in the Global Equity category with an average
ALTAR Score™ of 4.4% and a standard deviation
of 2.7%. HELX's ALTAR Score™ is approximately -2.0 standard
deviations above the category average. This places HELX in the 2nd percentile
among funds in the category.
Sell-Side Consensus
$43.71
PRICE TARGET
+32.0%
UPSIDE
Bid/Ask Spreads
52 bp
AVG SPREAD
27 —
622 bp
RANGE